BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Laroprovstat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Laroprovstat\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07000136-1050@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000136)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Pa
 tients With HeFH\nEstimated primary completion: 4 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07000136
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000123-1050@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000123)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Pa
 tients With Clinical ASCVD or at Risk for a First ASCVD Event\nEstimated p
 rimary completion: 11 January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/laroprovstat#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07000123
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06834932-1050@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Laroprovstat: Phase 2/3 readout est. (NCT06834932)
DESCRIPTION:Laroprovstat\, phase 2/3\, Atherosclerotic Cardiovascular Disea
 se.\nStudy: A Study to Evaluate the Efficacy\, Safety\, and Pharmacokineti
 cs of AZD0780 in Participants With Dyslipidaemia\nEstimated primary comple
 tion: 22 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/laroprovstat#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06834932
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-1050@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07619131)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin and Placebo on LDL-C in 
 LLT-naïve Patients.\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07619131
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-1050@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07930507)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin\, and Placebo on LDL-C i
 n LLT-naïve Patients\nEstimated primary completion: 11 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07930507
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000357-1050@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20291026
DTEND;VALUE=DATE:20291027
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000357)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study of AZD0780 on Major Adverse CV Events in Patie
 nts With a History of ASCVD Events or at High Risk for a First Event\nEsti
 mated primary completion: 26 October 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/laroprovstat#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07000357
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
